|
[1]
|
邓亚, 张珊, 纪冬. 慢性乙型肝炎低水平病毒血症的研究进展[J]. 传染病信息, 2021, 34(4): 342-346.
|
|
[2]
|
Zhang, Q., Cai, D.C., Hu, P. and Ren, H. (2021) Low-Level Viremia in Nucleoside Analog-Treated Chronic Hepatitis B Patients. Chinese Medical Journal (England), 134, 2810-2817. [Google Scholar] [CrossRef]
|
|
[3]
|
尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版) [J]. 传染病信息, 2023, 36(1): 1-17.
|
|
[4]
|
Lai, C.L., Wong, D., Philip, L.P., et al. (2017) Reduction of Covalently Closed Circular DNA with Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B. Journal of Hepatology, 66, 275-281. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Allweiss, L. and Dandri, M. (2017) The Role of cccDNA in HBV Maintenance. Viruses, 9, Article No. 156. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
樊正勤, 曹灵芝, 李文颖. 扬州地区67例慢性乙型肝炎低病毒血症患者临床特征分析[J]. 临床医药实践, 2022, 31(4): 265-267.
|
|
[7]
|
Pollicino, T. and Caminiti, G. (2021) HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses, 13, Article No. 368. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Tu, T., Zehnder, B., Qu, B., et al. (2021) De Novo Synthesis of Hepatitis B Virus Nucleocapsids Is Dispensable for the Maintenance and Transcriptional Regulation of cccDNA. JHEP Reports, 3, Article ID: 100195. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Wang, J., Huang, H., Liu, Y., et al. (2020) HBV Genome and Life Cycle. In: Tang, H., Ed., Hepatitis B Virus Infection: Molecular Virology to Antiviral Drugs, Springer, Berlin, 17-37. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
De Almeida, N.A.A. and de Paula, V.S. (2022) Occult Hepatitis B Virus (HBV) Infection and Challenges for Hepatitis Elimination: A Literature Review. Journal of Applied Microbiolo-gy, 132, 1616-1635. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
王雷婕, 顾智强, 许梓萌, 等. 核苷(酸)类药物经治慢性乙型肝炎患者低病毒血症发生的可能机制[J]. 中华肝脏病杂志, 2021, 29(12): 1151-1155.
|
|
[12]
|
Yan, Y., Allweiss, L., Yang, D., et al. (2019) Down-Regulation of Cell Membrane Localized NTCP Expression in Proliferating Hepatocytes Prevents Hepa-titis B Virus Infection. Emerging Microbes & Infections, 8, 879-894. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Jung, H.J., et al. (2018) Synthesis and Physicochemical Evaluation of Entecavir-Fatty Acid Conjugates in Reducing Food Effect on Intestinal Absorption. Molecules, 23, Article No. 731. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Shin, J.W., et al. (2018) Medication Nonadherence In-creases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated with Entecavir. American Journal of Gastroenterology, 113, 998-1008. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
韩宗儒, 闵晓春, 沈启刚, 等. 慢性乙型肝炎患者服用核苷(酸)类药物的依从性调查及其影响因素分析[J]. 肝脏, 2020, 25(11): 1148-1152.
|
|
[16]
|
Kim, J.H., Sinn, D.H., Kang, W., et al. (2017) Low-Level Viremia and the Increased Risk of Hepatocellular Carcinoma in Patients Receiving Entecavir Treatment. Hepatology, 66, 335-343. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Ogawa, E., Nomura, H., Nakamuta, M., et al. (2020) Tenofovir Alafenamide after Switching from Entecavir or Nucleos(t)ide Combination Therapy for Pa-tients with Chronic Hepatitis B. Liver International, 40, 1578-1589. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Lee, S.B., Jeong, J., Park, J.H., et al. (2020) Low-Level Viremia and Cir-rhotic Complications in Patients with Chronic Hepatitis B According to Adherence to Entecavir. Clinical and Molecular Hepatology, 26, 364-375. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
陈贺, 傅涓涓, 李丽, 等. 长期恩替卡韦经治慢性乙型肝炎患者低病毒血症的相关影响因素[J]. 临床肝胆病杂志, 2021, 37(3): 556-559.
|
|
[20]
|
Kim, H.J., Cho, Y.K., Jeon, W.K., et al. (2017) Clinical Characteristics of Patients with Chronic Hepatitis B Who Developed Genotypic Resistance to Entecavir: Real-Life Experience. Clinical and Molecular Hepatology, 23, 323-330. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
宣碧碧, 徐永红, 杜忠彩, 刘玉, 杨玉玲, 边城. 慢性乙型肝炎和乙型肝炎肝硬化患者发生低病毒血症的影响因素及其与肝脏炎症、肝纤维化进展的关系o-展[J]. 临床肝胆病杂志, 2022, 38(10): 2252-2259.
|
|
[22]
|
Sun, Y., Wu, X., Zhou, J., et al. (2020) Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression during Therapy. Clinical Gastroenterology and Hepatology, 18, 2582-2591. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Wang, H., Ru, G.Q., Yan, R., et al. (2016) Histologic Disease in Chinese Chronic Hepatitis B Patients with Low Viral Loads and Persistently Normal Alanine Aminotransferase Levels. Journal of Clinical Gastroenterology, 50, 790-796. [Google Scholar] [CrossRef]
|
|
[24]
|
赵西太, 聂青和. 重视慢性乙型肝炎临床管理中的低病毒血症[J]. 中西医结合肝病杂志, 2021, 31(7): 661-665.
|
|
[25]
|
Shin, S.K., Yim, H.J., Kim, J.H., et al. (2021) Partial Virological Response after2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis. Gut and Liver, 15, 430-439. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见[J]. 中华肝脏病杂志, 2022, 30(2): 131-136.
|
|
[27]
|
Terrault, N.A., Lok, A., McMahon, B.J., et al. (2018) Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 67, 1560-1599. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Wong, G.L., Wong, V.W., Chan, H.Y., et al. (2012) Undetectable HBV DNA at Month 12 of Entecavir Treatment Predicts Maintained Viral Suppression and HBeAg-Seroconversion in Chronic Hepatitis B Patients at 3 Years. Alimentary Pharmacology & Therapeutics, 35, 1326-1335. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Yin, G.Q., Li, J., Zhong, B., et al. (2021) New Therapeutic Options for Persistent Low-Level Viremia in Patients with Chronic Hepatitis B Virus Infection: Increase of Entecavir Dosage. World Journal of Gastroenterology, 27, 666-676. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
陈丽文, 祝达, 谢竟全, 张倩华, 高文军. 三种抗病毒治疗方案对ETV经治低病毒血症CHB患者HBV DNA转阴时间差异分析[J]. 海南医学, 2021, 32(6): 689-691.
|
|
[31]
|
Li, Z.B., Li, L., Niu, X.X., et al. (2021) Switching from Entecavir to Tenofovir Alafenamide for Chronic Hepatitis B Patients with Low-Level Viraemia. Liver International, 41, 1254-1264. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
陈文辉, 汤智勤, 高海兵. 富马酸替诺福韦单药或联合恩替卡韦治疗恩替卡韦治疗后的低病毒血症的慢乙肝的48周疗效观察[J]. 海峡药学, 2021, 33(5): 177-179.
|
|
[33]
|
Tamaki, N., Kurosaki, M., Nakanishi, H., et al. (2020) Comparison of Medica-tion Adherence and Satisfaction between Entecavir and Tenofovir Alafenamide Therapy in Chronic Hepatitis B. Journal of Medical Virology, 92, 1355-1358. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Chen, X.Y., Ren, S., Lu, J., et al. (2022) Combination Therapy in HBeAg-Negative Chronic Hepatitis B Patients with Low-Level Viremia to Nucleos (Tide) Analogues. Journal of Hepa-tology, 77, S844. [Google Scholar] [CrossRef]
|
|
[35]
|
Sulkowski, M.S., Agarwal, K., Ma, X., et al. (2022) Safety and Efficacy of Vebicorvir Administered with Entecavir in Treatment-Naïve Patients with Chronic Hepatitis B Virus In-fection. Journal of Hepatology, 77, 1265-1275. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Yuen, M.F., Agarwal, K., Ma, X., et al. (2022) Safety and Efficacy of Vebicorvir in Virologically Suppressed Patients with Chronic Hepatitis B Virus Infection. Journal of Hepatology, 77, 642-652. [Google Scholar] [CrossRef] [PubMed]
|